Sen. Donna Lowenthal has introduced the Illegal Ketamine Sales Prevention Act in the U.S. Senate, placing unlawful online sales of the drug at the center of a new federal crime-focused proposal.

The measure directs the Food and Drug Administration and the Drug Enforcement Administration to coordinate investigations involving unlawful online ketamine sellers. It also calls on the agencies to pursue available enforcement remedies and notify relevant internet and payment services.

The bill’s introduction begins the legislative process but does not itself settle whether the proposal will advance. No vote or other Senate action on the measure was included in the available information.

Lowenthal’s proposal is focused on coordination among the two federal agencies and on contact with services that can play a role in online commerce. The summary identifies investigations of unlawful sellers, enforcement under existing remedies and notifications to internet and payment providers as the bill’s principal elements.

That emphasis makes the measure a narrower law-enforcement proposal than broader debates over drug policy or medical regulation. The bill, as described, centers on online sellers operating outside lawful channels rather than establishing a general framework for ketamine use or treatment.

The introduction comes as crime and public-safety legislation remains a visible part of Senate activity. Other recent Senate coverage has focused on a separate proposal concerning public-safety grants and police support, underscoring how crime-related measures can move through Congress with different policy aims and different legislative paths.

For Lowenthal, the bill adds another Senate initiative to her recent legislative work. Earlier this month, the Senate began debate on her separate measure concerning disclosure and data accuracy in certain federal spending agreements. The ketamine-sales bill turns to a different policy area, using federal regulatory and enforcement agencies as the central instruments of the proposal.

The available summary does not specify additional provisions, a timetable for agency action or a date for Senate consideration. It also does not provide a cost estimate, list of co-sponsors or a stated position from Senate leadership.

Those details could shape the legislation’s prospects if it receives further consideration. For now, the Illegal Ketamine Sales Prevention Act is an introduced Senate bill seeking a coordinated federal response to unlawful online ketamine sales, with the FDA and DEA directed to investigate sellers, pursue existing enforcement options and alert relevant online and payment-sector services.